FDA advisory panel to discuss Eli Lilly's Alzheimer's drug, donanemab, on 10 June.

An FDA advisory panel will meet on June 10 to discuss Eli Lilly's Alzheimer's drug, donanemab, for early symptomatic Alzheimer's disease. Donanemab, which targets beta amyloid protein, has faced two regulatory delays in the US. The FDA will evaluate the drug's safety and effectiveness in a public meeting. A similar therapy by Eisai and Biogen, Leqembi, received FDA approval last year.